Literature DB >> 8625000

Cost of allogeneic and autologous blood transfusion in Canada. Canadian Cost of Transfusion Study Group.

R Tretiak1, A Laupacis, M Rivière, K McKerracher, E Souêtre.   

Abstract

OBJECTIVE: To determine the cost, from a societal perspective, of blood transfusion in Canada. STUDY
DESIGN: Cost-structure analysis.
SETTING: Data were collected from eight hospitals and from six blood centres operated by the Canadian Red Cross Society in four provinces. OUTCOME MEASURES: Costs associated with four stages of transfusion-- collection, production, distribution and delivery--in 1933 were assessed. Costs were divided into the following categories; personnel, purchases, external services, overhead, donors' time, patients' time (for autologous transfusion), wastage and infection.
RESULTS: The mean overall cost of a transfusion performed on an inpatient basis was $210 per unit of red blood cells for an allogeneic transfusion and $338 per unit of blood for an autologous transfusion. The mean cost of an allogeneic transfusion performed on an outpatient basis was $280 per unit of red blood cells.
CONCLUSION: The costs determined in this study can be used in future studies comparing the cost-effectiveness of allogeneic transfusion with that of alternative methods.

Entities:  

Mesh:

Year:  1996        PMID: 8625000      PMCID: PMC1487839     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  7 in total

1.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.

Authors:  A Laupacis; D Feeny; A S Detsky; P X Tugwell
Journal:  CMAJ       Date:  1992-02-15       Impact factor: 8.262

2.  The hospital cost (fiscal year 1991/1992) of a simple perioperative allogeneic red blood cell transfusion during elective surgery at Duke University.

Authors:  D A Lubarsky; C Hahn; D H Bennett; L R Smith; S J Bredehoeft; H G Klein; J G Reves
Journal:  Anesth Analg       Date:  1994-10       Impact factor: 5.108

3.  The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada.

Authors:  S Sheingold; D Churchill; N Muirhead; A Laupacis; R Labelle; R Goeree
Journal:  Soc Sci Med       Date:  1992-05       Impact factor: 4.634

4.  The lifetime cost of treating a person with HIV.

Authors:  F J Hellinger
Journal:  JAMA       Date:  1993-07-28       Impact factor: 56.272

5.  Evaluation of red blood cell transfusion practices with the use of preset criteria.

Authors:  W A Ghali; A Palepu; W G Paterson
Journal:  CMAJ       Date:  1994-05-01       Impact factor: 8.262

6.  The declining risk of post-transfusion hepatitis C virus infection.

Authors:  J G Donahue; A Muñoz; P M Ness; D E Brown; D H Yawn; H A McAllister; B A Reitz; K E Nelson
Journal:  N Engl J Med       Date:  1992-08-06       Impact factor: 91.245

7.  A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis.

Authors:  B S Bloom; A L Hillman; A M Fendrick; J S Schwartz
Journal:  Ann Intern Med       Date:  1993-02-15       Impact factor: 25.391

  7 in total
  12 in total

1.  A decision model and cost analysis of intra-operative cell salvage during hepatic resection.

Authors:  Madeline Lemke; Gareth Eeson; Yulia Lin; Jordan Tarshis; Julie Hallet; Natalie Coburn; Calvin Law; Paul J Karanicolas
Journal:  HPB (Oxford)       Date:  2016-03-09       Impact factor: 3.647

Review 2.  Clinical and economic impact of epoetins in cancer care.

Authors:  Monia Marchetti; Giovanni Barosi
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

3.  Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery.

Authors:  D Coyle; K M Lee; D A Fergusson; A Laupacis
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

4.  A cost-analysis comparison of laparoscopic radical prostatectomy versus open radical prostatectomy: the McMaster Institute of Urology experience.

Authors:  Tariq F Al-Shaiji; Niki Kanaroglou; Achilleas Thom; Connie Prowse; Vikram Comondore; William Orovan; Kevin Piercey; Paul Whelan; Leo Winter; Edward D Matsumoto
Journal:  Can Urol Assoc J       Date:  2010-08       Impact factor: 1.862

5.  A cost-utility analysis of treatments for malignant liver tumours: a pilot project.

Authors:  Andrew McKay; Trish Kutnikoff; Mark Taylor
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

6.  Prospective economic evaluation alongside the non-invasive ventilation trial.

Authors:  M E Mowitz; J A F Zupancic; D Millar; H Kirpalani; J S Gaulton; R S Roberts; W Mao; D Dukhovny
Journal:  J Perinatol       Date:  2016-09-29       Impact factor: 2.521

Review 7.  Tranexamic acid for major spinal surgery.

Authors:  David T Neilipovitz
Journal:  Eur Spine J       Date:  2004-05-04       Impact factor: 3.134

8.  A novel autotransfusion device saving erythrocytes and platelets used in a 72 h survival swine model of surgically induced controlled blood loss.

Authors:  Kévin Schreiber; Benoit Decouture; Audrey Lafragette; Stéphane Chollet; Marine Bruneau; Maxence Nicollet; Catherine Wittmann; Francis Gadrat; Alexandre Mansour; Patricia Forest-Villegas; Olivier Gauthier; Gwenola Touzot-Jourde
Journal:  PLoS One       Date:  2022-03-24       Impact factor: 3.240

Review 9.  Perioperative blood management strategies for patients undergoing total knee replacement: Where do we stand now?

Authors:  Tzatzairis Themistoklis; Vogiatzaki Theodosia; Kazakos Konstantinos; Drosos I Georgios
Journal:  World J Orthop       Date:  2017-06-18

10.  Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia.

Authors:  G Barosi; M Marchetti; N L Liberato
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.